´ëÇÑ°£ÇÐȸ The Liver Week 2019 DAY 2 : 2019-06-21±³À°ÀÏÀÚ : 2019-06-21
±³À°Àå¼Ò : ºÎ»ê º¤½ºÄÚ ROOM A [1F] 103-105 / 108-110, ROOM B [1F] 101, ROOM C [1F] 102, ROOM BC [1F] 101-102, ROOM D [1F] 106, ROOM E [1F] 107, ROOM A [2F] 201-202, ROOM B [2F] 203, ROOM D [2F] 205
±³À°ÁÖÁ¦ :
The Liver Week 2019 DAY 2ÁÖÃÖ±â°ü : ´ëÇÑ°£ÇÐȸ
´ã´çÀÚ : ´ëÇÑ°£ÇÐȸ
¿¬¶ôó : 02-703-0051
À̸ÞÀÏ :
kasl@kams.or.kr ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 1200¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
ºÎ»ê±¤¿ª½Ã±³À°½Ã°£ : 23 ½Ã°£ 35ºÐ
¼¼ºÎ¼ö°·á : 200,000¿ø
ºñ°í »çÀüµî·Ï: ȸ¿ø 140000/ÀüÀÓ 80000/ºñȸ¿ø 170000 ÇöÀåµî·Ï: ȸ¿ø 150000/ÀüÀÓ 100000/ºñȸ¿ø 200000
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 06-21 ROOM A [1F] 103-105 / 108-110 08:30~08:50 Fecal Microbiota Transplant in Alcohol-Related Liver Diseases SM Shasthry(Institute of Liver and Biliary Sciences, India)
±³À°½Ã°£ 06-21 ROOM A [1F] 103-105 / 108-110 08:50~09:10 Systemic Manifestation in Non-Alcoholic Fatty Liver Disease Donghee Kim(Stanford Univ., USA)
±³À°½Ã°£ 06-21 ROOM A [1F] 103-105 / 108-110 09:10~09:30 Update on the Management of Non-Alcoholic Fatty Liver Disease Vincent Wong(The Chinese Univ. of Hong Kong, Hong Kong)
±³À°½Ã°£ 06-21 ROOM A [1F] 103-105 / 108-110 11:10~11:25 Nucleoside Analogue NUC) Treatment Can Be Discontinued Chun-Jen Liu(National Taiwan Univ., Taiwan)
±³À°½Ã°£ 06-21 ROOM A [1F] 103-105 / 108-110 11:25~11:40 NUC Treatment Should Be Continued Young-Suk Lim(Univ. of Ulsan)
±³À°½Ã°£ 06-21 ROOM A [1F] 103-105 / 108-110 11:40~12:10 Panel Discussion Hyung Joon Yim, Wai-Kay Seto(Korea Univ. , Univ. of Hong Kong, Hong Kong)
±³À°½Ã°£ 06-21 ROOM A [1F] 103-105 / 108-110 13:30~14:00 Hepatitis B Virus: From Control to Cure Jia-Horng Kao(Taiwan National Univ., Taiwan)
±³À°½Ã°£ 06-21 ROOM A [1F] 103-105 / 108-110 14:00~14:20 Viral factors for Hepatitis B Virus-Related Hepatocellular Carcinoma Jeong Won Jang(The Catholic Univ. of Korea)
±³À°½Ã°£ 06-21 ROOM A [1F] 103-105 / 108-110 14:20~14:40 Novel Biomarkers in Management of Chronic Hepatitis B Yasuhito Tanaka(Nagoya City Univ., Japan)
±³À°½Ã°£ 06-21 ROOM A [1F] 103-105 / 108-110 14:40~15:00 Current Treatment Strategy: Toward Hepatitis B Virus Cure Seng Gee Lim(National Univ. of Singapore, Singapore)
±³À°½Ã°£ 06-21 ROOM A [1F] 103-105 / 108-110 15:00~15:20 Future Treatment Strategy: Toward Hepatitis B Virus Cure Henry LY Chan(The Chinese Univ. of Hong Kong, Hong Kong)
Åä·Ð 06-21 ROOM A [1F] 103-105 / 108-110 15:20~15:30 Discussion ()
±³À°½Ã°£ 06-21 ROOM A [1F] 103-105 / 108-110 16:30~16:50 Chronic Hepatitis B: Where Are We Now for Functional Cure? Hyun Woong Lee(Yonsei Univ.)
±³À°½Ã°£ 06-21 ROOM A [1F] 103-105 / 108-110 16:50~17:10 Non-Alcoholic Steatohepatitis: Key Targets and Endpoints Byoung Kuk Jang(Keimyung Univ.)
±³À°½Ã°£ 06-21 ROOM A [1F] 103-105 / 108-110 17:10~17:30 Cirrhosis: Effort against Fibrosis and Portal Hypertension Kyung-Ah Kim(Inje Univ.)
±³À°½Ã°£ 06-21 ROOM A [1F] 103-105 / 108-110 17:30~17:50 Hepatocellular Carcinoma Treatment Showdown: Mono vs. Combination Therapy Ju Hyun Shim(Univ. of Ulsan)
±³À°½Ã°£ 06-21 ROOM B [1F] 101 07:30~07:55 Management of Cirrhotic Complications: Guidelines and Real Experience C. Rinaldi A. Lesmana(Univ. of Indonesia, Indonesia)
±³À°½Ã°£ 06-21 ROOM B [1F] 101 07:55~08:20 Key Summary of EASL Clinical Practice Guidelines for the Management of Patients with Decompensated Cirrhosis Paolo Angeli(Univ. of Padova, Italy)
Åä·Ð 06-21 ROOM B [1F] 101 08:20~08:30 Discussion ()
±³À°½Ã°£ 06-21 ROOM C [1F] 102 07:30~07:50 Recent Epidemiology of Non-Alcoholic Fatty Liver Disease Donghee Kim(Stanford Univ., USA)
±³À°½Ã°£ 06-21 ROOM C [1F] 102 07:50~08:10 Non-Alcoholic Fatty Liver Disease and Diabetes: Chicken or Egg? Eun-Jung Rhee(Sungkyunkwan Univ.)
Åä·Ð 06-21 ROOM C [1F] 102 08:10~08:30 Discussion ()
±³À°½Ã°£ 06-21 ROOM BC [1F] 101-102 11:10~11:25 Treatment of Chronic Hepatitis B and C Eileen L. Yoon(Inje Univ.)
±³À°½Ã°£ 06-21 ROOM BC [1F] 101-102 11:25~11:40 Management of Acute Variceal Bleeding Seung Kak Shin(Gachon Univ.)
±³À°½Ã°£ 06-21 ROOM BC [1F] 101-102 11:40~11:55 Liver Transplantation: When and How? Bum Soo Kim(Kyung Hee Univ.)
±³À°½Ã°£ 06-21 ROOM BC [1F] 101-102 11:55~12:10 Hepatocellular Carcinoma: Diagnosis and Tumor Staging Woo Jin Chung(Keimyung Univ.)
±³À°½Ã°£ 06-21 ROOM D [1F] 106 11:10~11:25 Exceptional Insurances in the Field of End-Stage Liver Disease Jeong Han Kim(Konkuk Univ.)
±³À°½Ã°£ 06-21 ROOM D [1F] 106 11:25~11:40 Policy of KASL for Elimination of Hepatitis Sung Eun Kim(Hallym Univ.)
±³À°½Ã°£ 06-21 ROOM D [1F] 106 11:40~11:55 Liver Disease-Related Issue to Strengthen Health Insurance Coverage Expansion Policy Eun Sun Jang(Seoul National Univ.)
±³À°½Ã°£ 06-21 ROOM D [1F] 106 11:55~12:10 Future Policy of Government for Administration of Chronic Liver Disease Young Ki Jeong(Ministry of Health and Welfare)
±³À°½Ã°£ 06-21 ROOM D [1F] 106 14:00~14:20 Overview of Hepatitis Prevention and Control in the Republic of Korea Sung Won Lee(The Catholic Univ. of Korea)
±³À°½Ã°£ 06-21 ROOM D [1F] 106 14:20~14:40 National Viral Hepatitis Control Plan Don Han Lee(Korea Centers for Disease Control and Prevention)
±³À°½Ã°£ 06-21 ROOM D [1F] 106 14:40~14:55 Korea HBV Cohort Study Beom Kyung Kim(Yonsei Univ.)
±³À°½Ã°£ 06-21 ROOM D [1F] 106 14:55~15:10 Korea HCV Cohort Study Eun Sun Jang(Seoul National Univ.)
Åä·Ð 06-21 ROOM D [1F] 106 15:10~15:30 Discussion ()
±³À°½Ã°£ 06-21 ROOM E [1F] 107 14:00~14:20 Comparison of Bone Marrow-derived Mesenchymal Stem Cells Isolated from Normal and Cirrhotic Patients Young Woo Eom(Yonsei Univ. Wonju)
±³À°½Ã°£ 06-21 ROOM E [1F] 107 14:20~14:40 Feasibility of Enhanced PRL-1 in Placenta-derived Mesenchymal Stem Cells by Gene Modification on a Rat Model with Hepatic Failure Gi Jin Kim(CHA Univ.)
±³À°½Ã°£ 06-21 ROOM E [1F] 107 14:40~15:00 Vascularized Liver Tissue with Different Types of Endothelial Cells and Recovery Aids for Acute Liver Failure Soo Hyun Kim(KIST)
±³À°½Ã°£ 06-21 ROOM E [1F] 107 15:00~15:20 MicroRNA Profile Analysis in Liver Fibrotic Tissue and Hepatic Differentiated Human Bone Marrow-derived Mesenchymal Stem Cells Jung Hoon Cha(The Catholic Univ. of Korea)
±³À°½Ã°£ 06-21 ROOM E [1F] 107 15:20~15:40 Proteomics Approach for Translational Research, Focusing on Liver Disease Kyung Kon Kim(Univ. of Ulsan)
±³À°½Ã°£ 06-21 ROOM A [2F] 201-202 08:30~09:00 Updated Liver Allograft Pathology Chris Bellamy(The Univ. of Edinburgh, Scotland)
±³À°½Ã°£ 06-21 ROOM A [2F] 201-202 09:00~09:30 Is it Need Protocol Biopsy in Liver Recipient? Suk Kyun Hong(Seoul National Univ.)
±³À°½Ã°£ 06-21 ROOM A [2F] 201-202 11:10~11:25 Pathological Point of View of Combined HCC and CCC: What Is the Origin and Diagnostic Criteria of Combined HCC and CCC Young Nyun Park(Yonsei Univ.)
±³À°½Ã°£ 06-21 ROOM A [2F] 201-202 11:25~11:40 Imaging Features of Combined HCC and CCC: What Is the Difference Compared with HCC or CCC? Chang-Hee Lee(Korea Univ.)
±³À°½Ã°£ 06-21 ROOM A [2F] 201-202 11:40~11:55 Surgical Treatment and Prognosis of Combined HCC and CCC Matsuyama Ryusei(Yokohama City Univ., Japan)
±³À°½Ã°£ 06-21 ROOM A [2F] 201-202 11:55~12:10 Issues of Combined HCC and CCC in Liver Transplantation Young Seok Han(Kyungpook National Univ.)
±³À°½Ã°£ 06-21 ROOM A [2F] 201-202 13:30~14:00 Donation after Circulatory Death Liver Procurement in Real Practice Koji Hashimoto(Cleveland Clinic, USA)
±³À°½Ã°£ 06-21 ROOM A [2F] 201-202 14:10~14:30 Current Status and Problems of Organ Donation Won Hyun Cho(Korea Organ Donation Agency)
±³À°½Ã°£ 06-21 ROOM A [2F] 201-202 14:30~14:50 Current Status of Liver Allocation System Jae Geun Lee(Yonsei Univ.)
±³À°½Ã°£ 06-21 ROOM A [2F] 201-202 14:50~15:10 Institutional Issue and Limit of Donation after Cardiac Death Dong-Sik Kim(Korea Univ.)
Åä·Ð 06-21 ROOM A [2F] 201-202 15:10~15:30 Panel Discussion Jeong-Rim Lee(Korea Organ Donation Agency, TBD)
±³À°½Ã°£ 06-21 ROOM A [2F] 201-202 16:30~16:50 HRS: Definition, Pathophysiology and Medical Management Yeon Seok Seo(Korea Univ.)
±³À°½Ã°£ 06-21 ROOM A [2F] 201-202 16:50~17:10 When to Consider SLK and How to Prevent Adverse Renal Outcome after Liver Transplantation Jae Min Chun(Kyungpook National Univ.)
±³À°½Ã°£ 06-21 ROOM A [2F] 201-202 17:10~17:30 MELD Purgatory in HRS and Allocation Policy: When to Start Renal Replacement Therapy? Shin Hwang(Univ. of Ulsan)
±³À°½Ã°£ 06-21 ROOM A [2F] 201-202 17:30~17:50 Optimal Time to Start Renal Replacement Therapy: Nephrologist Hye Ryoun Jang(Sungkyunkwan Univ.)
±³À°½Ã°£ 06-21 ROOM B [2F] 203 14:10~14:30 Recovery Management for Old Age Recipient Man Ki Ju(Yonsei Univ.)
±³À°½Ã°£ 06-21 ROOM B [2F] 203 14:30~14:50 Transplantation Counseling for old Age Recipient Hyung Sook Kim(Seoul St. Mary)
±³À°½Ã°£ 06-21 ROOM B [2F] 203 14:50~15:10 Acute Liver Failure Dong Jin Joo(Yonsei Univ.)
±³À°½Ã°£ 06-21 ROOM B [2F] 203 15:10~15:30 Patient Management after Liver Transplantation Seung Heui Hong(Samsung Medical Center)
±³À°½Ã°£ 06-21 ROOM D [2F] 205 08:30~08:50 Surveillances for HCC in Patients with NAFLD Vincent Wong(The Chinese Univ. of Hong Kong, Hong Kong)
±³À°½Ã°£ 06-21 ROOM D [2F] 205 08:50~09:10 Are Emerging Biomarkers and Imaging Tools Better than Routine Abdominal Sonography for HCC Surveillance? Do Young Kim(Yonsei Univ.)
±³À°½Ã°£ 06-21 ROOM D [2F] 205 09:10~09:30 Is LI-RADS Better for Diagnosis of HCC Jeong Min Lee(Seoul National Univ.)
±³À°½Ã°£ 06-21 ROOM D [2F] 205 11:10~11:25 0202 Liver Day Special Lecture Hyun Woong Lee(Yonsei Univ.)
±³À°½Ã°£ 06-21 ROOM D [2F] 205 13:30~13:50 Circulating Tumor Cells and Cell-Free Nucleic Acids Takahiiro Ochiai(Tokyo Medical Univ., Japan)
±³À°½Ã°£ 06-21 ROOM D [2F] 205 13:50~14:10 CAR-Associated Adoptive Immunotherapy Yutaka Kawakami(Keio Univ., Japan)
±³À°½Ã°£ 06-21 ROOM D [2F] 205 14:10~14:30 Oncolytic Virus-Based Therapy for HCC Jeong Heo(Pusan National Univ.)
±³À°½Ã°£ 06-21 ROOM D [2F] 205 14:30~14:45 Recent Trends of Treatment for Intermediate Stage HCC: Japanese Experience Masatoshi Kudo(Kindai Univ., Japan)
±³À°½Ã°£ 06-21 ROOM D [2F] 205 14:45~15:00 Recent Trends of Treatment for Intermediate Stage HCC: Korean Experience Ji Hoon Kim(Korea Univ.)
±³À°½Ã°£ 06-21 ROOM D [2F] 205 15:00~15:15 Recent Trends of Treatment for Advanced Stage HCC: Japanese Experience Kazuomi Ueshima(Kindai Univ., Japan)
±³À°½Ã°£ 06-21 ROOM D [2F] 205 15:15~15:30 Recent Trends of Treatment for Advanced Stage HCC: Korean Experience Won Young Tak(Kyungpook National Univ.)
±³À°½Ã°£ 06-21 ROOM D [2F] 205 16:30~16:50 First Line Treatments for HCC Arndt Vogel(Hannover Medical School, Germany)
±³À°½Ã°£ 06-21 ROOM D [2F] 205 16:50~17:10 Second Line Treatments for HCC Anthony El-Khoueiry(Univ. of Southern California Norris Comprehensive Cancer Center, USA)
±³À°½Ã°£ 06-21 ROOM D [2F] 205 17:10~17:30 A Future of Systemic Agents: Emerging Therapies and Strategies Baek-Yeol Ryoo(Univ. of Ulsan)
±³À°½Ã°£ 06-21 ROOM D [2F] 205 17:30~17:50 Combination of Interventional and Systemic Therapies: Current Status and Future Direction Joong-Won Park(National Cancer Center Korea)